Erasca (ERAS) Net Cash Flow Growth (1y) (2021 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 198.34% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 467.41% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14,223.53% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 453.08% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -125.22% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 53.46% |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | -1,067.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,067.88% |
| Dec 31, 2025 | 411.95% |
| Sep 30, 2025 | 103.93% |
| Jun 30, 2025 | -104.52% |
| Mar 31, 2025 | 116.78% |
| Dec 31, 2024 | 94.21% |
| Sep 30, 2024 | -300.84% |
| Jun 30, 2024 | 171.72% |
| Mar 31, 2024 | -42.65% |
| Dec 31, 2023 | -130.46% |
| Sep 30, 2023 | 67.08% |
| Jun 30, 2023 | -279.09% |
| Mar 31, 2023 | 57.77% |
| Dec 31, 2022 | 176.13% |
| Sep 30, 2022 | -127.21% |
| Jun 30, 2022 | -159.99% |
| Mar 31, 2022 | -125.92% |
| Dec 31, 2021 | -2,640.16% |
| Sep 30, 2021 | 788.92% |